{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.3"},{"groupId":"OG001","value":"56.8"},{"groupId":"OG002","value":"68.2"},{"groupId":"OG003","value":"52.3"},{"groupId":"OG004","value":"79.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"70"}],"units":"Participants"}],"title":"Ext. Baseline (BL): Non/absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5"},{"groupId":"OG001","value":"23.9"},{"groupId":"OG002","value":"20.5"},{"groupId":"OG003","value":"30.7"},{"groupId":"OG004","value":"13.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"12"}],"units":"Participants"}],"title":"Ext. BL: Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1"},{"groupId":"OG001","value":"12.5"},{"groupId":"OG002","value":"10.2"},{"groupId":"OG003","value":"12.5"},{"groupId":"OG004","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"5"}],"units":"Participants"}],"title":"Ext. BL: Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1"},{"groupId":"OG001","value":"4.5"},{"groupId":"OG002","value":"1.1"},{"groupId":"OG003","value":"3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Ext. BL: Severe"},{"categories":[{"measurements":[{"groupId":"OG001","value":"2.3"},{"groupId":"OG003","value":"1.1"},{"groupId":"OG004","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Ext. BL: Very severe"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Ext. BL: Not done"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"},{"groupId":"OG003","value":"100.0"},{"groupId":"OG004","value":"100.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"88"},{"groupId":"OG002","value":"88"},{"groupId":"OG003","value":"88"},{"groupId":"OG004","value":"88"}],"units":"Participants"}],"title":"Ext. BL: Total"},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6"},{"groupId":"OG001","value":"51.1"},{"groupId":"OG002","value":"54.5"},{"groupId":"OG003","value":"43.2"},{"groupId":"OG004","value":"67.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"59"}],"units":"Participants"}],"title":"Most extr. post-BL:tot Non/absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5"},{"groupId":"OG001","value":"22.7"},{"groupId":"OG002","value":"26.1"},{"groupId":"OG003","value":"33.0"},{"groupId":"OG004","value":"22.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"20"}],"units":"Participants"}],"title":"Most extr. post-BL: total Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2"},{"groupId":"OG001","value":"18.2"},{"groupId":"OG002","value":"14.8"},{"groupId":"OG003","value":"13.6"},{"groupId":"OG004","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"Most extr. post-BL: total Mod."},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"6.8"},{"groupId":"OG002","value":"4.5"},{"groupId":"OG003","value":"8.0"},{"groupId":"OG004","value":"2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"title":"Most extr. post-BL: total Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3"},{"groupId":"OG001","value":"1.1"},{"groupId":"OG003","value":"2.3"},{"groupId":"OG004","value":"1.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}],"units":"Participants"}],"title":"Most extr. post-BL: tot. Very severe"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Most extr. post-BL: total Not done"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"88"},{"groupId":"OG002","value":"88"},{"groupId":"OG003","value":"88"},{"groupId":"OG004","value":"88"}],"units":"Participants"}],"description":"Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).","groups":[{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG000","title":"Pasireotide LAR Overall - Acromegaly Symptom: Headache"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG001","title":"Pasireotide LAR Overall - Acromegaly Symptom: Fatigue"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG002","title":"Pasireotide LAR Overall - Acromegaly Symptom: Perspiration"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG003","title":"Pasireotide LAR Overall - Acromegaly Symptom: Osteoarthralgia"},{"description":"This is the sum total of participants who were treated with at least one dose of pasireotide LAR in the extension phase","id":"OG004","title":"Pasireotide LAR Overall - Acromegaly Symptom: Paresthsiae"}],"paramType":"NUMBER","populationDescription":"Extension FAS included all the patients who received at least one dose of pasireotide LAR in the extension phase.","reportingStatus":"POSTED","timeFrame":"Weeks 48, 60 & 72","title":"Extension (Ext.) Phase: Percentage of Participants With Acromegaly Shift Symptoms From Extension Baseline to Most Extreme Post-extension Baseline","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}